VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced a technical milestone with the successful detection of nucleosomes in capillary blood from critically ill patients with sepsis using a lateral flow finger-prick prototype. The study, conducted as part of the SUMMIT program, demonstrated the feasibility of detecting nucleosomes in capillary samples. The findings also support the feasibility of early detection of immune disruptions associated with conditions such as sepsis across point-of-care and non-laboratory settings.
The company said the prototype builds on prior results showing correlation between venous blood samples tested with its lateral flow system and its established Nu.Q nucleosome assay. Volition noted that this approach could expand access to testing through point-of-care use and broaden its addressable market while supporting future commercialization efforts, including potential partnerships to increase access in regions with limited laboratory infrastructure.
For more details, the full press release is available at https://ibn.fm/ioEmu.
Volition is a multinational company focused on advancing the science of epigenetics. Through its subsidiaries, Volition is developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life.
This breakthrough is significant because sepsis is a life-threatening condition that requires rapid diagnosis and treatment. Current diagnostic methods often rely on venous blood samples processed in central laboratories, which can delay results. A finger-prick test that can be performed at the point of care could dramatically reduce time to diagnosis and treatment, potentially saving lives. Moreover, the ability to use capillary blood makes testing feasible in remote or resource-limited settings where laboratory infrastructure is scarce.
The successful detection of nucleosomes in capillary blood marks a critical step toward commercializing a point-of-care test for sepsis. Volition's approach leverages its proprietary Nu.Q technology, which detects nucleosomes—fragments of DNA and proteins released into the bloodstream during cell death, a hallmark of sepsis. By adapting this technology to a lateral flow format similar to a pregnancy test, Volition aims to make sepsis testing as simple and accessible as possible.
The implications of this announcement extend beyond sepsis. The same technology could potentially be applied to other conditions involving immune disruption, such as autoimmune diseases or certain cancers. Volition's focus on expanding access to testing aligns with global health priorities to reduce disparities in healthcare delivery.
For further information about Volition, visit the company's website at www.Volition.com.
